IP Verse

Combinations And Modes Of Administration Of Therapeutic Agents And Combination Therapy - EP3248600

The patent EP3248600 was granted to Abraxis Bioscience on Jun 24, 2020. The application was originally filed on Feb 21, 2006 under application number EP17165979A. The patent is currently recorded with a legal status of "Revoked".

EP3248600

ABRAXIS BIOSCIENCE
Application Number
EP17165979A
Filing Date
Feb 21, 2006
Status
Revoked
Jun 25, 2021
Publication Date
Jun 24, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKApr 24, 2020ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSApr 9, 2020D YOUNGADMISSIBLE

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2004143004
DESCRIPTIONUS2005004002
DESCRIPTIONUS2006003931
DESCRIPTIONUS2006013819
DESCRIPTIONUS5470571
DESCRIPTIONUS5558864
DESCRIPTIONUS5690928
DESCRIPTIONUS5859018
DESCRIPTIONUS5916596
DESCRIPTIONUS6096331
DESCRIPTIONUS6506405
DESCRIPTIONUS6537579
DESCRIPTIONUS6566405
DESCRIPTIONWO0064437
DESCRIPTIONWO2005000900
DESCRIPTIONWO2005117978
DESCRIPTIONWO2005117986
OPPOSITIONEP0577215
OPPOSITIONEP0797988
OPPOSITIONEP1632259
OPPOSITIONWO0071079
OPPOSITIONWO0189522
OPPOSITIONWO2005030171
OPPOSITIONWO9503036
SEARCHWO0189522

Non-Patent Literature (NPL) Citations (150) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- A. C. CHAN, CURR. OPIN. IMMUNOL, (1996), vol. 8, no. 3, pages 394 - 401
DESCRIPTION- A. F. WILKS, PROGRESS IN GROWTH FACTOR RESEARCH, (1990), vol. 2, pages 97 - 111
DESCRIPTION- ALTMAYER ET AL., ARZNEIMITTELFORSCHUNG, (1995), vol. 45, pages 1053 - 6
DESCRIPTION- BERTOLINI ET AL., CANCER RES, (2003), vol. 63, no. 15, pages 4342 - 4346
DESCRIPTION- BOCCI ET AL., CANCER RES, (2002), vol. 62, pages 6938 - 6943
DESCRIPTION- BOCCI ET AL., PNAS, (2003), vol. 100, no. 22, pages 12917 - 12922
DESCRIPTION- CANCER CHEMOTHER. PHARMACOL., (2004), vol. 53, pages 363 - 9
DESCRIPTION- CARTER ET AL., ADV. PROTEIN. CHEM., (1994), vol. 45, pages 153 - 203
DESCRIPTION- CURRY ET AL., NAT. STRUCT. BIOL., (1998), vol. 5, pages 827 - 35
DESCRIPTION- FEHSKE ET AL., BIOCHEM. PHARMCOL., vol. 30, pages 687 - 92
DESCRIPTION- FINLAYSON, SEMINARS IN THROMBOSIS AND HEMOSTASIS, (1980), vol. 6, pages 85 - 120
DESCRIPTION- FOLKMAN ET AL., "Tumor Angiogenesis (ch.10)", FOLKMAN ET AL., MENDELSOHN ET AL., The Molecular Basis of Cancer, W. B. SAUNDERS, (1995), pages 206 - 32
DESCRIPTION- FOLKMAN, J., CANCER RES., (1986), vol. 46, pages 467 - 73
DESCRIPTION- FOLKMAN, J. NAT. CANCER INST., (1989), vol. 82, pages 4 - 6
DESCRIPTION- GARRIDO ET AL., REV. ESP. ANESTESTIOL. REANIM., (1994), vol. 41, pages 308 - 12
DESCRIPTION- GELDERBLOM ET AL., CLIN. CANCER RES., (2002), vol. 8, pages 1237 - 41
DESCRIPTION- GEORGES; SHAROM; LING, "Multidrug Resistance and Chemosensitization: Therapeutic Implications for Cancer Chemotherapy", ADVANCES IN PHARMACOLOGY, (1990), vol. 21, pages 185 - 220, XP000957493
DESCRIPTION- HE ET AL., NATURE, vol. 358, pages 209 - 15
DESCRIPTION- HOUSER ET AL., SURGERY, GYNECOLOGY AND OBSTETRICS, (1980), vol. 150, pages 811 - 816
DESCRIPTION- J. A. COOPER, SEMIN. CELL BIOL., (1994), vol. 5, no. 6, pages 377 - 387
DESCRIPTION- JIMENEZ; YUNIS, CANCER RESEARCH, (1992), vol. 52, pages 413 - 415
DESCRIPTION- KRAGH-HANSEN, DAN. MED. BULL., (1990), vol. 1441, pages 131 - 40
DESCRIPTION- KUZMICH; TEW, DETOXIFICATION MECHANISMS AND TUMOR CELL RESISTANCE TO ANTICANCER DRUGS
DESCRIPTION- LORENZ ET AL., AGENTS ACTIONS, (1987), vol. 7, pages 63 - 67
DESCRIPTION- NAT MED., (199909), vol. 5, no. 9, pages 1032 - 8
DESCRIPTION- NAT. MED, (1999), vol. 5, no. 9, pages 1032 - 8
DESCRIPTION- NG ET AL., CANCER RES., (2004), vol. 64, pages 821 - 824
DESCRIPTION- O'REILLY ET AL., CELL, (1994), vol. 79, pages 315 - 28
DESCRIPTION- O'REILLY ET AL., CELL, (1997), vol. 88, pages 277 - 85
DESCRIPTION- PAAL ET AL., EUR. J. BIOCHEM., vol. 268, no. 7, pages 2187 - 91
DESCRIPTION- PURCELL ET AL., BIOCHIM. BIOPHYS. ACTA, (2000), vol. 1478, no. A, pages 61 - 8
DESCRIPTION- RASPAGLIO, BIOCHEMICAL PHARMACOLOGY, (2005), vol. 69, pages 113 - 121
DESCRIPTION- R. F. PAULSON, SEMIN. IMMUNOL., (1995), vol. 7, no. 4, pages 267 - 277
DESCRIPTION- S. A. COURTNEIDGE, DEV., (1993), vol. 1, pages 57 - 64
DESCRIPTION- SHAKED ET AL., CANCER CELL, (2005), vol. 7, pages 101 - 111
DESCRIPTION- SHIAU ET AL., J. PHARM. SCI., (1978), vol. 67, no. 3, pages 394 - 397
DESCRIPTION- SUGIO ET AL., PROTEIN. ENG.,, (1999), vol. 1?, pages 439 - 46
DESCRIPTION- TEISCHER ET AL., INT. J. CANCER, (1994), vol. 57, pages 920 - 25
DESCRIPTION- "The Multidrug-Resistant Phenotype (MDR", MEDICAL RESEARCH REVIEWS, (1991), vol. 11, no. 2, pages 185 - 217
DESCRIPTION- TULLIS, JAMA, (1977), vol. 237, pages 355 - 360,460-463
DESCRIPTION- URIEN ET AL., INVEST. NEW DRUGS, (1996), vol. 14, no. B, pages 147 - 51
DESCRIPTION- VORUM, DAN. MED. BULL., (1999), vol. 46, pages 379 - 99
DESCRIPTION- VREDENBURG ET AL., JNCI, (2001), vol. 93, pages 1234 - 1245
DESCRIPTION- WEIDNER, NEW ENG. J. MED., (1991), vol. 324, no. 1, pages 1 - 8
DESCRIPTION- WEISS ET AL., J. CLIN. ONCOL., (1990), vol. 8, pages 1263 - 68
OPPOSITION- Albain Kathy S., J J Crowley , M Leblanc , R B Livingston, "Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience", Journal of Clinical Oncology, (19910101), vol. 9, pages 1618 - 1626, XP093009448
OPPOSITION- Alberola V., C. Camps , M. Provencio , D. Isla , R. Rosell , C. Vadelli. Bover , A. Ruiz-Casado , P. Azagra , U. Jiménez , J.L. González-Larriba , P. Diz , F. Cardenal , A. Artal , A. Carrato , S. Morales , J.J. Sánchez , R. De Las Peñas , E. Felip , G. López-Vivanco, "Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial", Journal of Clinical Oncology, (20030101), vol. 21, pages 3207 - 3213, XP093009493
OPPOSITION- Al Housseini A., Daugherty P., Sofidiya M., Burrel M. Boverie J., Benogno B., "A phase II, non-randomized study of abraxane plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer: Evaluation of side effects and tolerability ", Journal of Clinical Oncology, Meeting Abstract 2008 ASCO Meeting, (20080520), vol. 26, no. 15suppl., page 16556, XP093008877
OPPOSITION- Anonymou, "ABRAXANE Meets Primary Endpoints in Phase 3 Trial for Advanced Non-Small- Cell Lung Cancer", Press Release BioSpace, (20100317), URL: www.biospace.com/news_print.aspx?NewsEntityId=174173, XP093009547
OPPOSITION- Anonymous, "Abraxane® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)", FDA, (20050107), pages 1 - 26, XP055716894
OPPOSITION- Anonymous, "American Pharmaceutical Partners and American BioScience Announce FDA Acceptance of New Drug Application of Abraxane for the Treatment of Metastatic Breast Cancer", Drugs.com, (20040510), pages 1 - 2, XP055716886
OPPOSITION- Anonymous, Cancer Facts & Figures, (20090101), pages 1 - 70, XP093009231
OPPOSITION- Anonymous, "Drugs in R&D ABI-007 (Abraxane)", Drugs R D, (20040000), vol. 5, no. 4, pages 155 - 159, XP055716913
OPPOSITION- BELANI, "Paclitaxel/Carboplatin in the Treatment of Non-Small- Cell Lung Cancer", ONCOLOGY, (19980102), vol. 12, no. 1, pages 74 - 79, XP002741576
OPPOSITION- Benigno B.B., Burrell M.O., Daugherty P., Hernandez P., "A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer", Journal of Clinical Oncology, Meeting Abstract 2010 ASCO Annual Meeting I, (20100520), vol. 28, no. 15suppl., page 5011, XP093008898
OPPOSITION- Bunn, Jr Paul, "The expanding role of cisplatin in the treatment of non-small-cell lung cancer", Seminars in Oncology, (19890801), vol. 16, no. 4, suppl.6, pages 10 - 21, XP093009267
OPPOSITION- "Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer", (20150123), URL: https://s24.q4cdn.com/483522778/files/doc_news/archive/892620.pdf, XP093009680
OPPOSITION- "Chapter 25 - Lung", AJCC, Cancer Staging Manual, 7th ed., (20100101), pages 253 - 270, ISBN 978-0-387-88440-0, XP093009236
OPPOSITION- Coleman Robert L., Lin Yvonne G., Stone Rebecca L. Et Al., "Dual Metronomic Chemotherapy Results in Potent Anti-Angiogenic Effects in Ovarian Carcinoma", Poster MD Anderson Cancer Center, (20100101), XP093009056
OPPOSITION- Colomer Ramon, "Gemcitabine and Paclitaxel in Metastatic Breast Cancer: A Review", Oncology, (20041201), vol. 18, no. 14suppl, pages 8 - 12, XP093008558
OPPOSITION- Crino L., G. V. Scagliotti , S. Ricci , F. De Marinis , M. Rinaldi , C. Gridellia. Ceribelli , R. Bianco , M. Marangolo , F. Di Costanzo , M. Sassi , S. Barni , A. Ravaioli , V. Adamo , L. Portalone , G. Cruciani , A. Masotti , G. Ferrara , F. Gozzelino , M. Tonato, "Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project ", Journal of Clinical Oncology, (19990101), vol. 17, pages 3522 - 3530, XP093009476
OPPOSITION- DAMASCELLI B, ET AL., "A NOVEL INTRAARTERIAL CHEMOTHERAPY USING PACLITAXEL IN ALBUMIN NANOPARTICLES TO TREAT ADVANCED SQUAMOUS CELL CARCINOMA OF THE TONGUE: PRELIMINARY FINDINGS", AMERICAN JOURNAL OF ROENTGENOLOGY, US , (20030701), vol. 181, no. 01, ISSN 0361-803X, pages 253 - 260, XP009041095
OPPOSITION- Daniel D. Von Hof f , Thomas J. Erv in, Francis P. Arena, E. Gabriela Chiorean, Jef f rey R. Inf ante, Malcolm J. Moore, Thomas E. Seay, Sergei Tjulandin, Wen Wee Ma, Mansoor N. Saleh, Marion Harris, Michele Reni, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, Eric Van Cutsem, Dav id Goldstein, Xiny u Wei, Jose Luis Iglesias, Markus Frederic Renschler; Virginia G., "Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). | 2013 Gastrointestinal Cancers Symposium | Abstracts | Meeting Library", Journal of Clinical Oncology, Meeting Abstract, US , (20130101), vol. 34, no. suppl. 4, ISSN 0732-183X, page LBA148, XP055262676
OPPOSITION- Di Leo A., Gomez, H, Aziz Z, Zvirbule Z, Arbushites M, Oliva Cr, "Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients | ", Journal of Clinical Oncology, Meeting Abstract 2007 ASCO Annual Meeting, (20070620), vol. 25, no. 18suppl., page 1011, XP093009050
OPPOSITION- "Doxorubicin ", Wikipedia, (20140812), URL: https://en.wikipedia.org/w/index.php?title=Doxorubicin&oldid=620954907, XP093009621
OPPOSITION- El-Khoueiry A.B., Iqbal S., Lenz H. Et Al., "A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC)", Journal of Clinical Oncology, Meeting Abstract 2011 ASCO Annual Meeting, (20110520), vol. 29, no. 15suppl., page 4124, XP093009059
OPPOSITION- "Erlotinib ", Wikipedia, (20140924), XP093009626
OPPOSITION- Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao, and Silverio Tomao, "Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.", INTERNATIONAL JOURNAL OF NANOMEDICINE, (20090420), vol. 4, pages 99 - 105, XP008159055
OPPOSITION- Fossella Frank, Jose R. Pereira , Joachim Von Pawel , Anna Pluzanska , Vera Gorbounova , Eckhard Kaukelkarin V. Mattson , Rodryg Ramlau , Aleksandra Szczęsna , Panagiotis Fidias , Michael Millward , Chandra P. Belani, "Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group", Journal of Clinical Oncology, (20030101), vol. 21, no. 16, pages 3016 - 3024, XP093009524
OPPOSITION- Gatzemeier Ulrich, Joachim Von Pawel , Maya Gottfried , G.P. M. Ten Velde , Karin Mattson , Filipo Demarinispeter Harper , Franco Salvati , Gilles Robinet , Antonio Lucenti , Jan Bogaerts , Gilles Gallant, "Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer ", Journal of Clinical Oncology, (20000101), vol. 18, pages 3390 - 3399, XP093009341
OPPOSITION- Grilli Roberto, A D Oxman , J A Julian, "Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?", Journal of Clinical Oncology, (19930101), vol. 11, pages 1866 - 1872, XP093009452
OPPOSITION- Hodi F. Stephen, Soiffer Robert J., Clark Jeffrey Finkelstein Dianne M., Haluska Frank G., "Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma", American Journal of Clinical Oncology, (20020101), vol. 25, no. 3, pages 283 - 286, XP093008933
OPPOSITION- Ilson David H., A Forastiere, M Arquette, F Costa, R Heelan, Y Huang, D P Kelsen, "A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus", The Cancer Journal, (20000901), vol. 6, no. 5, pages 316 - 323, XP093009610
OPPOSITION- J.A. O'SHAUGHNESSY et al., "Abstract 1070 - 27th Annual Charles A Coltman San Antonio Breast Cancer Symposium", Breast Cancer Research and Treatment, San Antonio, TX, USA D2, (20041208), vol. 88, no. 1, page S65, XP019274693
OPPOSITION- Jones Christopher M., Earnhardt Pamela, "Targeted Therapies for NSCLC", US Pharm., (20071018), vol. 32, no. 10, pages 5 - 13, XP093009246
OPPOSITION- Kaklamani V, Uthe R, Khan S, Bethke K, Jeruss J, Cianfrocca M, Von Roenn J, Rosen S, Gradishar W, "1091 - Pilot Neoadjuvant Trail With Combination of Lapatinib and Nab-Paclitaxel in HER2 + Breast Cancer", Poster Session 1: Treatment: Neoadjuvant Therapy, (20091210), XP093009043
OPPOSITION- Kelly Karen, John Crowley , Paul A. Bunn Jr , Cary A. Presant , Patra K. Grevstad , Carol M. Moinpourscott D. Ramsey , Antoinette J. Wozniak , Geoffrey R. Weiss , Dennis F. Moore , Valerie K. Israel , Robert B. Livingston , David R. Gandara, "Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial", Journal of Clinical Oncology, (20010101), vol. 19, pages 3210 - 3218, XP093009519
OPPOSITION- Kosmidis Paris, Nick Mylonakis , Costas Nicolaides , Charalabos Kalophonos , Epaminontas Samantas , John Boukovinasgeorge Fountzilas , Dimosthenis Skarlos , Theophanis Economopoulos , Dimitrios Tsavdaridis , Pavlos Papakostas , Charalabos Bacoyiannis , Meletios Dimopoulos, "Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial", Journal of Clinical Oncology, (20020101), vol. 20, pages 3578 - 3585, XP093009522
OPPOSITION- Kottschade L.A., Suman V.J., Amatruda Iii T., Mcwilliams R.R., Dakhil S.R., Nikcevich D.A., "A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E ", Journal of Clinical Oncology, Meeting Abstract 2008 ASCO Annual Meeting, (20080520), vol. 26, no. 15suppl., page 9044, XP093008909
OPPOSITION- Le Chevalier Thierry, D Brisgand , J Y Douillard , J L Pujol , V Alberola , A Monnier, A Riviere , P Lianes , P Chomy , S Cigolari Et Al., "Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients", Journal of Clinical Oncology, (19940201), vol. 12, no. 2, pages 360 - 367, XP093009317
OPPOSITION- LI C, ET AL., "COMPLETE REGRESSION OF WELL-ESTABLISHED TUMORS USING A NOVEL WATER-SOLUBLE POLY(L-GLUTAMIC ACID)-PACLITAXEL CONJUGATE", Cancer research, US, (19980601), vol. 58, no. 11, ISSN 0008-5472, pages 2404 - 2409, XP000986297
OPPOSITION- Lowry Fran, "Drug Combo Shrinks Pancreatic Tumors in Phase I Trial", GI & Hepatology News, (20081101), page 14, XP093009063
OPPOSITION- Lynch, T. Kim, E., "Optimizing chemotherapy and targeted agent combinations in NSCLC", LUNG CANCER, NL , (20051201), vol. 50, ISSN 0169-5002, pages S25 - S32, XP005343480
OPPOSITION- Miller Kathy D., "E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer", Clinical Breast Cancer, (20030201), vol. 3, no. 6, pages 421 - 422, XP093009088
OPPOSITION- "Neoplastic Disorders", MIMS, (20050101), pages 332 - 343, XP093008546
OPPOSITION- Paz I.B., Lau S., Garberoglio C., Luu T.H., Chung C.T., Mortimer J., "Nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC) ", Journal of Clinical Oncology, (20080520), vol. 26, no. 15suppl., page 567, XP093008968
OPPOSITION- Rajeshkumar N.V., Shinichi Yabuuchi, Shweta G. Pai, Scott Bateman, Ellen Filvaroff, Daniel W. Pierce, Carla Heise, Daniel D. Von Hoff, Anirban Maitra, Manuel Hidalgo, "Highlights of innovative preclinical studies which guided the rapid bench to bedside development of nab-paclitaxel plus gemcitabine combination for the treatment of pancreatic cancer", Poster Johns Hopkins Medicine Center, (20140101), XP093009666
OPPOSITION- RIGAS JAMES R, "Taxane-platinum combinations in advanced non-small cell lung cancer: a review.", THE ONCOLOGIST, (20040101), vol. 9, no. 2, ISSN 1083-7159, pages 16 - 23, XP002570454
OPPOSITION- Sandler A.B., J. Nemunaitis , C. Denham , J. Von Pawel , Y. Cormier , U. Gatzemeierk. Mattson , Ch. Manegold , M.C. Palmer , A. Gregor , B. Nguyen , C. Niyikiza , L.H. Einhorn, "Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer", Journal of Clinical Oncology, (20000101), vol. 18, pages 122 - 130, XP093009327
OPPOSITION- SANDLER ALAN, ET AL, "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer", The New England journal of medicine, US , (20061214), vol. 355, no. 24, ISSN 0028-4793, pages 2542 - 2550, XP002593420
OPPOSITION- Scagliotti G.V., F. De Marinis , M. Rinaldi , L. Crinò , C. Gridelli , S. Riccie. Matano , C. Boni , M. Marangolo , G. Failla , G. Altavilla , V. Adamo , A. Ceribelli , M. Clerici , F. Di Costanzo , L. Frontini , M. Tonato ,, "Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer ", Journal of Clinical Oncology, (20020101), vol. 20, pages 4285 - 4291, XP093009520
OPPOSITION- SCHILLER J H , ET AL, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.", New England Journal of Medicine, The - NEJM, US , (20020110), vol. 346, no. 2, ISSN 1533-4406, pages 92 - 98, XP002385282
OPPOSITION- Somer B.G., Schwartzberg L.S., Arena F., Epperson A., Fu D., Fortner B.V., "Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC) ", Journal of Clinical Oncology, Meeting Abstract 2007 ASCO Annual Meeting, (20070620), vol. 25, no. 18suppl., page 1053, XP093008947
OPPOSITION- Wasserheit Carolyn, A Frazein , R Oratz , J Sorich , A Downey , H Hochstera Chachoua , J Wernz , A Zeleniuch-Jacquotte , R Blum , J Speyer, "Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity", Journal of Clinical Oncology, (19960101), vol. 14, no. 7, pages 1993 - 1999, XP093009605
OPPOSITION- Wozniak Antoinette J., J J Crowley, S P Balcerzak, G R Weiss, C H Spiridonidis, L H Baker, K S Albain, K Kelly, S A Taylor, D R Gandara, R B Livingston, "Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study", Journal of Clinical Oncology, (19980101), vol. 16, pages 2459 - 2465, XP093009343
OPPOSITION- Yardley Da, Meluch A, Murphy P, Doss H, Simons L, Hart L, Daniel B, Burris Iii Ha, "Preliminary Results From a Multicenter Phase II Trail of Biweekly Neoadjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) With Correlative SPARC Tumor Analysis", Poster Session III: Treatment: Neoadjuvant Therapy, (20061215), XP093009038
OPPOSITION- Zhang Xiaodong, Shen, Lin; Li, Jie; Li, Yan; Li, Jian; Jin, Maolin , "A Phase II Trial of Paclitaxel and Cisplatin in Patients With Advanced Squamous-Cell Carcinoma of the Esophagus", American Journal of Clinical Oncology, (20080201), vol. 31, no. 1, pages 29 - 33, XP093009613
OPPOSITION- Damascelli Bruno; Cantu Giulio; Mattavelli Franco; Tamplenizza Paolo; Bidoli Paolo; Leo Ermanno; Dosio Franco; Cerrotta Anna M; Di Tolla Giuseppe; Frigerio Laura F; Garbagnati Francesco; Lanocita Rodolfo; Marchiano Alfonso; Patelli Gianluigi; Spreafico Carlo; Ticha Vladimira; Vespro Valentina; Zunino Franco, "Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence of clinical activity", Cancer, US , (20011115), vol. 92, no. 10, doi:10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4, ISSN 0008-543X, pages 2592 - 2602, XP009521681
OPPOSITION- Ravi D. Rao, Shernan G. Holtan, James N. Ingle, Gary A. Croghan, Lisa A. Kottschade, Edward T. Creagan, Judith S. Kaur, Henry C. Pitot, Svetomir N. Markovic, "Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma", Cancer, (20060115), vol. 106, no. 2, doi:10.1002/cncr.21611, ISSN 0008543X, pages 375 - 382, XP055100303
OPPOSITION- Evan M. Hersh, Steven J. O'day, Antoni Ribas, Wolfram E. Samlowski, Michael S. Gordon, Deganit E. Shechter, Alicia A. Clawson, Rene Gonzalez, "A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma", Cancer, US , (20090101), doi:10.1002/cncr.24720, ISSN 0008-543X, pages 155 - 163, XP055262317
OPPOSITION- Lisa A. Kottschade, Vera J. Suman, Thomas Amatruda, Robert R. Mcwilliams, Bassam I. Mattar, Daniel A. Nikcevich, Robert Behrens, Tom R. Fitch, Anthony J. Jaslowski, Svetomir N. Markovic, "A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma", Cancer, US , (20110415), vol. 117, no. 8, doi:10.1002/cncr.25659, ISSN 0008-543X, pages 1704 - 1710, XP055269698
OPPOSITION- Patrick A. Ott; Jason Chang; Kathleen Madden; Rajni Kannan; Caroline Muren; Crystal Escano; Xin Cheng; Yongzhao Shao; Sandra Mendoza; Alex Gandhi; Leonard Liebes; Anna C. Pavlick, "Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial", Cancer Chemotherapy and Pharmacology, Berlin, DE , (20121012), vol. 71, no. 1, doi:10.1007/s00280-012-1995-7, ISSN 1432-0843, pages 183 - 191, XP035157063
OPPOSITION- Hiroshi Kamiyama ; Shingo Takano ; Koji Tsuboi ; Akira Matsumura, "Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells", Journal of Cancer Research and Clinical Oncology, Berlin, DE , (20050401), vol. 131, no. 4, doi:10.1007/s00432-004-0642-z, ISSN 1432-1335, pages 205 - 213, XP019345398
OPPOSITION- STINCHCOMBE et al., "Preliminary results of phase I trial of carboplatin (CP) in combination with ABI-007 administered weekly or every 3 weeks in patients (pts) with solid tumors", Breast Cancer Research and Treatment, (20051200), vol. 94, no. 1, page 71, XP009068639
OPPOSITION- STINCHCOMBE T E, et al., "PRELIMINARY RESULTS OF PHASE I TRIAL OF CARBOPLATIN (CP) IN COMBINATION WITH ABI-007 ADMINISTERED WEEKLY OR EVERY 3 WEEKS IN PATIENTS (PTS) WITH SOLID TUMORS", Breast Cancer Research and Treatment, New York, (20050101), vol. 94, no. SUPPL. 01, doi:10.1007/s10549-005-7328-3, ISSN 0167-6806, page S71, XP009068639
OPPOSITION- Sorensen, J.B. ; Osterlind, K. ; Hansen, H.H., "Vinca alkaloids in the treatment of non-small cell lung cancer", Cancer Treatment Reviews, AMSTERDAM, NL , (19870301), vol. 14, no. 1, doi:10.1016/0305-7372(87)90049-1, ISSN 0305-7372, pages 29 - 51, XP023271021
OPPOSITION- Li, C. ; Wallace, S., "Polymer-drug conjugates: Recent development in clinical oncology", Advanced Drug Delivery Reviews, Amsterdam , NL , (20080522), vol. 60, no. 8, doi:10.1016/j.addr.2007.11.009, ISSN 0169-409X, pages 886 - 898, XP022624677
OPPOSITION- Mirtsching Barry, Cosgriff Thomas, Harker Graydon, Keaton Mark, Chidiac Tarek, Min Myo, "A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer", Clinical Breast Cancer, US , (20110401), vol. 11, no. 2, doi:10.1016/j.clbc.2011.03.007, ISSN 1526-8209, pages 121 - 128, XP093009614
OPPOSITION- Satouchi Miyako, Okamoto Isamu, Sakai Hiroshi, Yamamoto Nobuyuki, Ichinose Yukito, Ohmatsu Hironobu, Nogami Naoyuki, Takeda Koji, Mitsudomi Tetsuya, Kasahara Kazuo, Negoro Shunichi, "Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer", LUNG CANCER, NL , (20130701), vol. 81, no. 1, doi:10.1016/j.lungcan.2013.02.020, ISSN 0169-5002, pages 97 - 101, XP093009551
OPPOSITION- Hoekstra, A.V. ; Hurteau, J.A. ; Kirschner, C.V. ; Rodriguez, G.C., "The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer", GYNECOLOGIC ONCOLOGY, GB , (20091201), vol. 115, no. 3, doi:10.1016/j.ygyno.2009.08.021, ISSN 0090-8258, pages 377 - 381, XP026733149
OPPOSITION- Robert L. Coleman; William E. Brady; D. Scott McMeekin; Peter G. Rose; John T. Soper; Samuel S. Lentz; James S. Hoffman; Mark S. Shahin;, "A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study", GYNECOLOGIC ONCOLOGY, GB , vol. 122, no. 1, doi:10.1016/j.ygyno.2011.03.036, ISSN 0090-8258, pages 111 - 115, XP028221419
OPPOSITION- Pirker, R. ; Pereira, J.R. ; Szczesna, A. ; von Pawel, J. ; Krzakowski, M. ; Ramlau, R. ; Vynnychenko, I. ; Park, K. ; Yu, C.T. ; Ganul, V. ; Roh, J.K. ; Bajetta, E. ; O'Byrne, K. ; de Marinis, F. ; Eberhardt, W. ; Goddemeier, T. ; Emig, M. ; Gatzemeier, U., "Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial", The Lancet, AMSTERDAM, NL , (20090502), vol. 373, no. 9674, doi:10.1016/S0140-6736(09)60569-9, ISSN 0140-6736, pages 1525 - 1531, XP026088699
OPPOSITION- Trieu, V. ; D'Cruz, O. ; Piacente, M. ; Huang, T. ; Faxon, S. ; Desai, N., "1224 Enhancement of antitumour activity of the vascular disrupting agent ABI-011 by nab-paclitaxel and bevacizumab", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, GB , (20090901), vol. 7, no. 2, doi:10.1016/S1359-6349(09)70436-7, ISSN 1359-6349, page 127, XP026560395
OPPOSITION- A. I. de Vos ; K. Nooter ; J. Verweij ; W. J. Loos ; E. Brouwer ; P. de Bruijn ; E. J. Ruijgrok ; M. E. L. van der Burg ; G. Stoter ; A. Sparreboom, "Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL", Annals of Oncology, GB , (19971101), vol. 8, no. 11, doi:10.1023/A:1008215720081, ISSN 1569-8041, pages 1145 - 1150, XP019228696
OPPOSITION- CARMELIET P., ET AL., "ANGIOGENESIS IN CANCER AND OTHER DISEASES", Nature, London, (20000914), vol. 407, no. 6801, doi:10.1038/35025220, ISSN 0028-0836, pages 249 - 257, XP000918984
OPPOSITION- GUBA M, ET AL., "RAPAMYCIN INHIBITS PRIMARY AND METASTATIC TUMOR GROWTH BY ANTIANGIOGENESIS: INVOLVEMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR", Nature Medicine, New York, (20020201), vol. 8, no. 2, doi:10.1038/nm0202-128, ISSN 1078-8956, pages 128 - 135, XP001095089
OPPOSITION- Onn A, Tsuboi M, Thatcher N, "Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib", British Journal of Cancer, London, (20040801), vol. 91, no. S2, doi:10.1038/sj.bjc.6602062, ISSN 0007-0920, pages S11 - S17, XP093009513
OPPOSITION- Eleni Sakkoula; Eva Pipili-Synetos; M. E. Maragoudakis, "Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2", British journal of pharmacology, UK , (20090205), vol. 122, no. 5, doi:10.1038/sj.bjp.0701436, ISSN 0007-1188, pages 793 - 795, XP071055736
OPPOSITION- Soffer Samuel Z., Kim Eugene, Moore James T., Huang Jianzhong, Yokoi Akiko, Manley Christina, O'toole Kathleen, Middlesworth William, Stolar Charles, Yamashiro Darrell, Kandel Jessica, "Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor", JOURNAL OF PEDIATRIC SURGERY, US , (20011201), vol. 36, no. 12, doi:10.1053/jpsu.2001.28823, ISSN 0022-3468, pages 1781 - 1784, XP093009632
OPPOSITION- Mccrudden Kimberly W., Yokoi Akiko, Thosani Amit, Soffer Samuel Z., Kim Eugene S., Huang Jianzhong, Manley Christina, O'toole Kathleen, Yamashiro Darrell J., Kandel Jessica J., Middlesworth William, "Topotecan is anti-angiogenic in experimental hepatoblastoma", JOURNAL OF PEDIATRIC SURGERY, US , (20020601), vol. 37, no. 6, doi:10.1053/jpsu.2002.32887, ISSN 0022-3468, pages 857 - 861, XP093009638
OPPOSITION- SLAMON D J, et al., "USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2", The New England journal of medicine, US , (20010315), vol. 344, no. 11, doi:10.1056/NEJM200103153441101, ISSN 0028-4793, pages 783 - 792, XP008019806
OPPOSITION- M. R. Green et al., "Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer", Annals of Oncology, NL , vol. 17, no. 8, doi:10.1093/annonc/mdl104, ISSN 0923-7534, pages 1263 - 1268, XP055394562
OPPOSITION- V. Roy, B. R. Laplant, G. G. Gross, C. L. Bane, F. M. Palmieri, "Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)", Annals of Oncology, vol. 20, no. 3, doi:10.1093/annonc/mdn661, ISSN 09237534, pages 449 - 453, XP055205000
OPPOSITION- M. A. Socinski, C. J. Langer, I. Okamoto, J. K. Hon, V. Hirsh, S. R. Dakhil, R. D. Page, J. Orsini, H. Zhang, M. F. Renschler, "Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer", Annals of Oncology, NL , (20130201), vol. 24, no. 2, doi:10.1093/annonc/mds461, ISSN 0923-7534, pages 314 - 321, XP055287824
OPPOSITION- GARBER, "Improved Paclitaxel Formulation - Hints at New Chemotherapy Approach", Journal of the National Cancer Institute, (20040121), vol. 96, no. 2, doi:10.1093/jnci/96.2.90, pages 90 - 91, XP055132631
OPPOSITION- Fuerst Mark L., "Metastatic breast cancer: Novel albumin-bound paclitaxel, ABI-007 (Abraxane) shows advantages over standard paclitaxel", Oncology Times, (20040810), vol. 26, doi:10.1097/01.COT.0000313239.25410.e3, page 9, XP093009079
OPPOSITION- Hosein Peter J., De Lima Lopes Jr, Gilberto; Pastorini, Vitor H. ; Gomez, Christina ; Macintyre, Jessica ; Zayas, Gloria ; Reis, Isildinha ; Montero, Alberto J. ; Merchan, Jaime R. ; Rocha Lima, Caio M. , "A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer", American Journal of Clinical Oncology, (20130401), vol. 36, no. 2, doi:10.1097/COC.0b013e3182436e8c, pages 151 - 156, XP093009028
OPPOSITION- Langer Corey J., O’byrne Kenneth J., Socinski Mark A., Mikhailov Sergei M., Leśniewski-Kmak Krzysztof, Smakal Martin, Ciuleanu Tudor E., Orlov Sergey V., Dediu Mircea, Heigener David, Eisenfeld Amy J., Sandalic Larissa, Oldham Fred B., Singer Jack W., Ross Helen J., "Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer", Journal of Thoracic Oncology, US , (20080601), vol. 3, no. 6, doi:10.1097/JTO.0b013e3181753b4b, ISSN 1556-0864, pages 623 - 630, XP093009081
OPPOSITION- N Desai, S Ran, L Volk, A Stutzman, O D'Cruz, V Trieu, "Antitumor activity, and antiangiogenic activity of nanoparticle albumin-bound nab-rapamycin in combination with nab-paclitaxel.", Cancer research, US, (20090115), vol. 69, no. 2, Suppl. S, doi:10.1158/0008-5472.SABCS-3125 , ISSN 0008-5472, page 239S, XP002678704
OPPOSITION- N. Casagrande, M. Celegato, C. Borghese, M. Mongiat, A. Colombatti, D. Aldinucci, "Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer", Clinical Cancer Research, US, (20141101), vol. 20, no. 21, doi:10.1158/1078-0432.CCR-14-0713, ISSN 1078-0432, pages 5496 - 5506, XP055469342
OPPOSITION- Laquente Berta, Lacasa Cristina, Ginesta; Mireia M., Casanovas Oriol, Figueras Agnes, Galan Maica, Ribas Ignacio Garcia, Germa Josep Ramon, Capella Gabriel, Vinals Francesc, "Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model", Molecular Cancer Therapeutics, US , (20080301), vol. 7, no. 3, doi:10.1158/1535-7163.MCT-07-2122, ISSN 1535-7163, pages 638 - 647, XP055808341
OPPOSITION- Awasthi Niranjan, Zhang Changhua, Schwarz Anna M., Hinz Stefan, Schwarz Margaret A., Schwarz Roderich E., "Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer", Molecular Cancer Therapeutics, US , (20140501), vol. 13, no. 5, doi:10.1158/1535-7163.MCT-13-0361, ISSN 1535-7163, pages 1032 - 1043, XP093009703
OPPOSITION- Davis Ashley N., Yvonne G. Lin-Liu; Rebecca A. Previs; Heather J. Dalton; Behrouz Zand; Justin Bottsford-Miller; Robert Coleman; Anil K. Sood, "Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer ", Cancer Res, (20140101), vol. 74, no. 19_suppl., doi:10.1158/1538-7445.AM2014-2995, page 2995, XP093009689
OPPOSITION- W. J. Gradishar, "Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer", Journal of Clinical Oncology, (20051101), vol. 23, no. 31, doi:10.1200/JCO.2005.04.937, ISSN 0732183X, pages 7794 - 7803, XP055089298
OPPOSITION- Blum Joanne L., Dees E. Claire, Chacko Aparna, Doane Lisa, Ethirajan Sukumar, Hopkins Judith, Mcmahon Richard, Merten Suzan, Negron Angel, Neubauer Marcus, Ilegbodu Des, Boehm Kristi A., Asmar Lina, O'shaughnessy Joyce A., "Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer", Journal of Clinical Oncology, US , (20060920), vol. 24, no. 27, doi:10.1200/JCO.2005.05.1383, ISSN 0732-183X, pages 4384 - 4390, XP093008957
OPPOSITION- Hawkins M.J., Georgy M., Makhson A., Cheporov S., Sergey O., Yablonsky P., Bhar P., Socinski M., "Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC) ", Journal of Clinical Oncology, Meeting Abstract 2006 ASCO Annual Meeting, (20060620), vol. 24, no. 18suppl., doi:10.1200/jco.2006.24.18_suppl.7132, page 7132, XP093009850
OPPOSITION- Belani Chandra P., Ramalingam Suresh, Perry Michael C., Larocca Renato V., Rinaldi David, Gable Preston S., Tester William J., "Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer", Journal of Clinical Oncology, US , (20080120), vol. 26, no. 3, doi:10.1200/JCO.2007.13.1912, ISSN 0732-183X, pages 468 - 473, XP093009543
OPPOSITION- DI LEO ANGELO ET AL, "Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.", Journal of Clinical Oncology, US , (20081201), vol. 26, no. 34, doi:10.1200/JCO.2008.16.2578, ISSN 0732-183X, pages 5544 - 5552, XP002591604
OPPOSITION- Teneriello Michael G., Tseng Paul C., Crozier Mark, Encarnacion Carlos, Hancock Kenneth, Messing Mark J., Boehm Kristi A., Williams Alicia, Asmar Lina, "Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer", Journal of Clinical Oncology, US , (20090320), vol. 27, no. 9, doi:10.1200/JCO.2008.18.9548, ISSN 0732-183X, pages 1426 - 1431, XP093008904
OPPOSITION- T D Tillmans, M P Lowe, L S Schwartzberg, M S Walker, E J Stepanski, "A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma", Journal of Clinical Oncology, (20100520), doi:10.1200/jco.2010.28.15_suppl.5009, XP055688145
OPPOSITION- M.A. Socinski et al., "Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).", Journal of Clinical Oncology, Meeting Abstract 2010 ASCO Annual Meeting II, vol. 28, no. 18suppl., doi:10.1200/jco.2010.28.18_suppl.lba7511, (20100620), Database accession no. LBA7511, URL: http://meetinglibrary.asco.org/print/579212, XP055340184
OPPOSITION- D. D. Von Hoff, Ramanathan Ramesh K, Borad Mitesh J, Laheru Daniel A, Smith Lon S, Wood Tina E, Korn Ronald L, Desai Neil, Trieu Vuong, Iglesias Jose L, Zhang Hui, Soon-Shiong Patrick, Shi Tao, Rajeshkumar N V, Maitra Anirban, Hidalgo Manuel, Ramana-Than Ramesh K, Virginia Tgen /, Piper G, Center Cancer, Mitesh ;, Borad J, Clinic Mayo, Ronald L, Rajeshku-Mar N V, The Sol, Goldman, Antonio San, Tx, Al, Igle-Sias Jose L, "Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial", Journal of Clinical Oncology, US , (20111201), vol. 29, no. 34, doi:10.1200/JCO.2011.36.5742, ISSN 0732-183X, pages 4548 - 4554, XP055243146
OPPOSITION- Lisa D Volk, Michael J Flister, Deena Chihade, Neil Desai, Vuong Trieu, Sophia Ran, "Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases", Neoplasia, Canada , (20110401), doi:10.1593/neo.101490, pages 327 - 338, XP055155218
OPPOSITION- Sun Si, Tang Lichen, Zhang Jian, Lv Fangfang, Wang Zhonghua, Wang Leiping, Zhang Qunling, Zheng Chunlei, Qiu Lixin, Jia Zhen, Lu Yunhua, Liu Guangyu, Shao Zhimin, Wang Biyun, Hu Xichun, "Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer", International journal of nanomedicine, New Zealand , (20140319), vol. 2014, no. 9, doi:10.2147/IJN.S58275, ISSN 1178-2013, pages 1443 - 1452, XP093009552
OPPOSITION- Shi Yan, Qin Rui, Wangzhi-Kuan, Dai Guang-Hai, "Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma", OncoTargets and Therapy, (20130524), vol. 6, doi:10.2147/OTT.S44406, pages 585 - 591, XP093009607
OPPOSITION- MORENO-ASPITIA A, PEREZ E A, "NORTH CENTRAL CANCER TREATMENT GROUP N0531: PHASE II TRIAL OF WEEKLY ALBUMIN-BOUND PACLITAXEL (ABI-008; ABRAXANE) IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH METASTATIC BREAST CANCER", Clinical Breast Cancer, US , (20050101), vol. 06, no. 04, doi:10.3816/CBC.2005.n.042, ISSN 1526-8209, pages 361 - 364, XP009068698
OPPOSITION- Blum Joanne L., Savin Ma, Edelman G, Pippen Je, Robert Nj, Geister Bv, Kirby Rl, Clawson A, O'shaughnessy Ja, "Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes", Clin Breast Cancer, (20070101), vol. 7, no. 11, doi:10.3816/CBC.2007.n.049, pages 850 - 856, XP093009031
OPPOSITION- Wu Hongju, Xin Yan, Xu Chongan, Xiao Yuping, "Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts", EXPERIMENTAL AND THERAPEUTIC MEDICINE, GR , (20120401), vol. 3, no. 4, doi:10.3892/etm.2012.448, ISSN 1792-0981, pages 650 - 654, XP093009643
OPPOSITION- O'regan Ruth, Sheryl Gabram; Toncred Styblo; Monica Rizzo; William Wood; Jayanthi Srinivasiah; William Jonas; Fred Schnell; Amy Adams; Rita Nahta; Amelia Zelnak , "Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer ", AACR Cancer Research, (20120101), vol. 72, no. 8 suppl., doi:1538-7445.AM2012-2703, XP093009549
SEARCH- KIM SU BYUNG, "Cancer Resea rch a nd Treatme nt INTRODUCTION", CANCER RESEARCH AND TREATMENT, (20011201), pages 469 - 473, XP055411588 [Y] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents